CAR-T cell therapy, tyrosine receptor kinase inhibitors and quadruplet approaches are reshaping the landscape for managing complex hematologic malignancies. However, advanced therapies also introduce significant challenges, from managing hypogammaglobulinemia in CAR-T cell therapy to mitigating toxicity with tyrosine kinase inhibitors. In this eBook, gain access to peer-reviewed journal content and expert insights to navigate the practicalities of cutting-edge treatments.
Highlights include:
- [REVIEW] Managing hypogammaglobulinemia in patients treated with CAR-T-cell therapy: key points for clinicians
- [DRUG PROFILE] The role of nelarabine in the treatment of T-cell acute lymphoblastic leukemia/lymphoma: challenges, opportunities and future directions
- [RESEARCH ARTICLE] Cancer care for people with significant mental health difficulties (SMHD) - patient perspectives
- [SHORT COMMUNICATION] A real-world analysis of tyrosine receptor kinase inhibitor-related toxicities in cancer treatment
- [INTERVIEW] The more the better? Quadruplets in newly diagnosed multiple myeloma
